All News

Teens.adolescents.kids

EULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care

Jack Cush, MD

EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.

Read Article
shingles_0.jpg

Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab

MedPage Today

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.

Read Article
psA.fil_.toes_.jpg

Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis

Jack Cush, MD

Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis. Both trials met their primary endpoint, demonstrating ACR20 efficacy after 16 weeks of treatment with DEUC compared with placebo.

Read Article
gout target T2T

Benefit of Achieving Target Serum Urate Levels in Gout with Chronic Kidney Disease

Jack Cush, MD

A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.

Read Article
RheumNow Podcast square

ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".

Read Article
sit,sedentary,couch,coffee,comfort

Sedentary Behavior Increases the Risk of Gout

Jack Cush, MD

NHANES national survey study shows that sedentary behavior is an independent risk factor for gout, especially in those without hyperuricemia. 

Read Article
lupus,nephritis,GN

Best of 2024: Upside/Downside of Steroids in Lupus Nephritis

Jack Cush, MD

A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis demonstrates both the benefits and harms to early glucocorticoid regimens on lupus outcomes.

Read Article
12 mos study of RCT 179 gout pts starting allopurinol finds that betw mos 6-12, gout flares went down. 38% had no flares, 19% had 1 flare, & 43% had >1 flare in 2nd 6 mos. # flares equates to control and impact of gout on outcomes. https://t.co/TMwXZStbJU

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatologist Survey: Active Lupus on pred + DMARD w/ (more than skin/Joint) organ & serologic activity- whats your preferred "add-on" drug?

Dr. John Cush RheumNow ( View Tweet)

Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/AEJmW95vud https://t.co/3NnKjHQJtv

Links:

Dr. John Cush RheumNow ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/ug2ZzzSrGi https://t.co/O6r1e8ioO0

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency https://t.co/Fkn26crcNX https://t.co/LJVa0TApid

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD. 30% of ILD has cough Chest CT 91% sensitive, 71% specific 5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/s5v3XD8QmC https://t.co/iP5yFWkQwb
Dr. John Cush RheumNow ( View Tweet)
post-hoc analysis 48 pts w/ SSc-ILD in the DESIRES trial (DBRPCT) showed that RTX efficacy on lung outcomes (FVC change) at 24 weeks was only seen in those with CRP levels ≥0.055 mg/dl, ΔppFVC was significantly higher w RTX vs PBO [difference 8%) https://t.co/92yfWEU1d8 https://t.co/tB9sd9VS1K

Links:

Dr. John Cush RheumNow ( View Tweet)
Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/Cbzi00xHdb https://t.co/JLSIyOdxKb

Links:

Dr. John Cush RheumNow ( View Tweet)
Algorithm for the treatment of calcinosis #calcinosis @RheumNow #ACR24 https://t.co/NZhP7Enzrp https://t.co/1mO8waM5DI

Links:

Dr. John Cush RheumNow ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/dr3M3cnjRG https://t.co/1wewEuJRAl

Links:

Dr. John Cush RheumNow ( View Tweet)
A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/PMVn5Pb1b3

Links:

Dr. John Cush RheumNow ( View Tweet)

Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency https://t.co/atoMR1YChT https://t.co/OeaF9QUGEz

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD. 30% of ILD has cough Chest CT 91% sensitive, 71% specific 5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/FKZyNU1s06 https://t.co/w5q0hOesEH
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×